Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and leukemia group B study 9311

Cancer

Volumn 97, Issue 6, 2003, Pages 1471-1480

  Szatrowski, Ted P ^a   Dodge, Richard K ^b   Reynolds, Carol ^c   Westbrook, Carol A ^d   Frankel, Stanley R ^e   Sklar, Jeffrey ^c   Stewart, Carleton C ^f   Hurd, David D ^g   Kolitz, Jonathan E ^h   Velez Garcia, Enrique ⁱ   Stone, Richard M ^j   Bloomfield, Clara D ^k   Schiffer, Charles A ^l   Larson, Richard A ^m,n  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Cancer and Leukemia Group B Statistical Center   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g WAKE FOREST UNIVERSITY   (United States)

^h NORTH SHORE UNIVERSITY HOSPITAL   (United States)

ⁱ UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^j DANA FARBER CANCER INSTITUTE   (United States)

^k OHIO STATE UNIVERSITY   (United States)

^l WAYNE STATE UNIVERSITY   (United States)

^m UNIVERSITY OF CHICAGO   (United States)

ⁿ Cancer and Leukemia Group B   (United States)

more..

Author keywords

Adult acute lymphoblastic leukemia; Anti B4 blocked ricin; High dose cytarabine; Lineage specific therapy; Minimal residual disease

Indexed keywords

ALEMTUZUMAB; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; BCR ABL PROTEIN; CD19 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; GENOMIC DNA; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOTOXIN; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B4 BLOCKED RICIN; PENTAMIDINE; PREDNISONE; RICIN; RICIN ANTIBODY; RITUXIMAB; T LYMPHOCYTE RECEPTOR; TIOGUANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOGENETICS; CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; DYSPNEA; FEBRILE NEUTROPENIA; FEVER; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKEMIA CELL; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MULTICENTER STUDY; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYTARABINE; FEMALE; GENES, ABL; HUMANS; IMMUNOCONJUGATES; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL; RICIN; TREATMENT OUTCOME;

EID: 0037443673     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11219     Document Type: Article

References (35)

1. Czuczman MS, Dodge RK, Stewart CC, et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8364. Blood. 1999;93:3931-3939.
2. Larson RA, Dodge RK, Burns CP, et al. A five-drug induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood. 1995;85:2025-2037.
3. Larson RA, Dodge RK, Linker CA. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB Study 9111. Blood. 1998;92:1556-1564.
4. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood. 1999;93:3983-3993.
5. Lambert JM, Goldmacher VS, Collinson AR, Nadler LM, Blattler WA. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res. 1991;51:6236-6242.
6. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63:1424-1433.
7. Lambert JM, McIntyre G, Gauthier MN, et al. The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. Biochemistry. 1991;30:3234-3247.
8. Rohatiner AZ, Bassan R, Batista R, et al. High dose cytosine arabinoside in the initial treatment of adults with acute lymphoblastic leukemia. Br J Cancer. 1990;62:454-458.
9. Weiss M, Maslak P, Feldman E, et al. Cytarabine with high-dose mitoxantrone induces rapid complete remission in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol. 1996;14:2480-2485.
10. Linker CA, Damon L, Ries CA, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20:2464-2471.
11. Cataland SR, Daugherty CK, Weseman EC, Larson RA. Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia. Leuk Lymph. 2001;41:297-307.
12. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547-561.
13. Morra E, Lazzarinio M, Inverardi D, et al. Systemic high dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma. J Clin Oncol. 1986;4:1207-1211.
14. Bennett JM, Catovsky D, Daniel M-T, et al. Proposals for the classification of acute leukemias. French-American-British (FAB) Co-operative Group. Br J Haematol. 1976;33:451-458.
15. Weiss RB, Vogelzang NJ, Peterson BA, et al. A successful system of scientific data audits for clinical trials: a report from the Cancer and Leukemia Group B. JAMA. 1993;270: 459-464.
16. Sambrook J, Fritsch E, Maniatis T. Isolation of DNA from mammalian cells. In: Nolan C, editor. Molecular cloning: a laboratory manual. Volume 2. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989:9.16-9.19.
17. Stock W, Westbrook CA, Peterson B, et al. Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 1997;15:26-36.
18. Longtine J, Fox E, Reynolds C, Sklar J. Molecular analysis of DNA rearrangements in leukemias and non-Hodgkin's lymphomas. In: Sons JW, editor. Current protocols in human genetics. Volume 2. Boston: John Wiley & Sons, 1995:10.4.6.
19. Bourguin A, Tung R, Galili N, Sklar J. Rapid, nonradioactive detection of clonal T cell receptor gene rearrangements in lymphoid neoplasms. Proc Natl Acad Sci USA. 1990;87:8536-8540.
20. Ausubel F, Brent R, Kingston R, et al. Current protocols in molecular cloning. Volume 1. Boston: John Wiley & Sons, Inc., 2000.
21. Simon R. Optimal two-stage designs for Phase II clinical trials. Control Clin Trials. 1989;10:1-10.
22. Ritz J, Pesando JM, Sallan SE, et al. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood. 1981;58:141-152.
23. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306:517-522.
24. Dillman RO. Monoclonal antibodies for treating cancer. Ann Intern Med. 1989;111:592-603.
25. Vitetta ES, Fulton RJ, May RD, Till M, Uhr JW. Redesigning nature's poisons to create anti-tumor reagents. Science. 1987;238:1098-1104.
26. Grossbard ML, Lambert JM, Goldmacher VS, Blattler WA, Nadler LM. Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin. Cancer Res. 1992;52:4200-4207.
27. Grossbard ML, Lambert JM, Goldmacher VS, et al. Anti-B4- blocked ricin: a Phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol. 1993;11:726-737.
28. Dinndorf P, Krailo M, Liu-Mares W, Frierdich S, Sondel P, Reaman G. Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma. J Immunother. 2001; 24:511-516.
29. Multani PS, O'Day S, Nadler LM, Grossbard ML. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res. 1998;4:2599-2604.
30. Grossbard ML, Fidias P, Kinsella J, et al. Anti-B4-blocked ricin: a Phase II trial of 7 day continuous infusion in patients with multiple myeloma. Br J Haematol. 1998;102:509-515.
31. Grossbard ML, Multani PS, Freedman AS, et al. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res. 1999;5:2392-2398.
32. Cheson BD. Rituximab: clinical development and future directions. Expert Opin Biol Ther. 2002;2:97-110.
33. Flynn IM, Byrd JC. Campath-IH monoclonal antibody therapy. Curr Opin Oncol. 2000;12:574-581.
34. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244-3254.
35. Stock W, Dodge RK, Vardiman JW, et al. Treatment of adult acute lymphoblastic leukemia: Phase II trial of dose intensification of daunorubicin and cytarabine followed by highdose methotrexate and intrathecal methotrexate in place of cranial irradiation. Blood. 2001;98:2472.